Comments
Loading...

Theravance Biopharma Analyst Ratings

TBPHNASDAQ
Logo brought to you by Benzinga Data
$8.41
-0.50-5.61%
At close: -
$8.41
0.000.00%
After Hours: 4:00 PM EDT
Q1 2025 Earnings were released on Thu May 8th, after the market close
The most recent conference call was at 17:00 PM, 6 days ago Click to view past webcast
Consensus Rating1
Buy
Highest Price Target1
$21.00
Lowest Price Target1
$9.00
Consensus Price Target1
$13.17

Theravance Biopharma Analyst Ratings and Price Targets | NASDAQ:TBPH | Benzinga

Theravance Biopharma Inc has a consensus price target of $13.17 based on the ratings of 6 analysts. The high is $21 issued by BTIG on April 12, 2024. The low is $9 issued by TD Cowen on August 6, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on February 27, 2025, February 25, 2025, and September 16, 2024, respectively. With an average price target of $15 between HC Wainwright & Co., there's an implied 78.36% upside for Theravance Biopharma Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Feb
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.0
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
TD Cowen
Leerink Partners
BTIG
SVB Leerink

1calculated from analyst ratings

Analyst Ratings for Theravance Biopharma

Buy NowGet Alert
02/27/2025Buy Now78.36%HC Wainwright & Co.
Douglas Tsao50%
$15 → $15ReiteratesBuy → BuyGet Alert
02/25/2025Buy Now78.36%HC Wainwright & Co.
Douglas Tsao50%
$15 → $15ReiteratesBuy → BuyGet Alert
09/16/2024Buy Now78.36%HC Wainwright & Co.
Douglas Tsao50%
$15 → $15ReiteratesBuy → BuyGet Alert
08/06/2024Buy Now78.36%HC Wainwright & Co.
Douglas Tsao50%
$20 → $15MaintainsBuyGet Alert
08/06/2024Buy Now7.02%TD Cowen
Marc Frahm14%
$10 → $9MaintainsHoldGet Alert
08/06/2024Buy Now18.91%Leerink Partners
David Risinger71%
$15 → $10DowngradeOutperform → Market PerformGet Alert
05/29/2024Buy Now137.81%HC Wainwright & Co.
Douglas Tsao50%
→ $20ReiteratesBuy → BuyGet Alert
05/14/2024Buy Now137.81%HC Wainwright & Co.
Douglas Tsao50%
$20 → $20ReiteratesBuy → BuyGet Alert
04/12/2024Buy Now149.7%BTIG
Julian Harrison37%
→ $21Initiates → BuyGet Alert
08/08/2023Buy Now137.81%HC Wainwright & Co.
Douglas Tsao50%
→ $20ReiteratesBuy → BuyGet Alert
05/09/2023Buy Now137.81%HC Wainwright & Co.
Douglas Tsao50%
$19 → $20MaintainsBuyGet Alert
02/28/2023Buy Now125.92%HC Wainwright & Co.
Douglas Tsao50%
→ $19Reiterates → BuyGet Alert
11/17/2022Buy Now66.47%SVB Leerink
David Risinger71%
$12 → $14MaintainsOutperformGet Alert
11/08/2022Buy Now125.92%HC Wainwright & Co.
Douglas Tsao50%
$12 → $19MaintainsBuyGet Alert
07/25/2022Buy Now18.91%Morgan Stanley
Vikram Purohit38%
$11 → $10MaintainsUnderweightGet Alert
05/23/2022Buy Now42.69%SVB Leerink
David Risinger71%
→ $12Initiates → OutperformGet Alert

FAQ

Q

What is the target price for Theravance Biopharma (TBPH) stock?

A

The latest price target for Theravance Biopharma (NASDAQ:TBPH) was reported by HC Wainwright & Co. on February 27, 2025. The analyst firm set a price target for $15.00 expecting TBPH to rise to within 12 months (a possible 78.36% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Theravance Biopharma (TBPH)?

A

The latest analyst rating for Theravance Biopharma (NASDAQ:TBPH) was provided by HC Wainwright & Co., and Theravance Biopharma reiterated their buy rating.

Q

When was the last upgrade for Theravance Biopharma (TBPH)?

A

There is no last upgrade for Theravance Biopharma

Q

When was the last downgrade for Theravance Biopharma (TBPH)?

A

The last downgrade for Theravance Biopharma Inc happened on August 6, 2024 when Leerink Partners changed their price target from $15 to $10 for Theravance Biopharma Inc.

Q

When is the next analyst rating going to be posted or updated for Theravance Biopharma (TBPH)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Theravance Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Theravance Biopharma was filed on February 27, 2025 so you should expect the next rating to be made available sometime around February 27, 2026.

Q

Is the Analyst Rating Theravance Biopharma (TBPH) correct?

A

While ratings are subjective and will change, the latest Theravance Biopharma (TBPH) rating was a reiterated with a price target of $15.00 to $15.00. The current price Theravance Biopharma (TBPH) is trading at is $8.41, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch